Compare · BBNX vs BDX
BBNX vs BDX
Side-by-side comparison of Beta Bionics Inc. (BBNX) and Becton Dickinson and Company (BDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBNX and BDX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $41.33B, about 66.9x BBNX ($618.1M).
- Over the past year, BBNX is down 26.9% and BDX is down 13.2% - BDX leads by 13.7 points.
- BBNX has been more active in the news (17 items in the past 4 weeks vs 10 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 16 for BBNX).
- Company
- Beta Bionics Inc.
- Becton Dickinson and Company
- Price
- $14.19+2.01%
- $149.79-0.23%
- Market cap
- $618.1M
- $41.33B
- 1M return
- +47.20%
- +0.25%
- 1Y return
- -26.89%
- -13.16%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 17
- 10
- Recent ratings
- 16
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BBNX
- Director Jones Christy sold $39,354 worth of shares (2,811 units at $14.00) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 27,400 units (SEC Form 4)
- Chief Commercial Officer Hopman Mark sold $3,385 worth of shares (275 units at $12.31) as part of a pre-agreed trading plan, decreasing direct ownership by 0.21% to 130,612 units (SEC Form 4)
- Chief Product Officer Mensinger Mike sold $55,194 worth of shares (4,378 units at $12.61), decreasing direct ownership by 2% to 184,415 units (SEC Form 4) (tax liability)
- Chief Commercial Officer Hopman Mark sold $67,183 worth of shares (5,329 units at $12.61), decreasing direct ownership by 4% to 130,887 units (SEC Form 4) to satisfy withholding tax
- President & CEO Saint Sean sold $212,707 worth of shares (16,872 units at $12.61), decreasing direct ownership by 4% to 420,937 units (SEC Form 4) to cover taxes
- Chief Medical Officer Russell Steven Jon sold $53,227 worth of shares (4,222 units at $12.61), decreasing direct ownership by 2% to 173,849 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Feider Stephen sold $84,165 worth of shares (6,676 units at $12.61), decreasing direct ownership by 4% to 166,053 units (SEC Form 4) to satisfy tax liability
- Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website
- Director Palasis Maria was granted 16,965 shares, increasing direct ownership by 136% to 29,397 units (SEC Form 4)
- Director Michel Gerard J was granted 16,965 shares, increasing direct ownership by 103% to 33,509 units (SEC Form 4)
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional